Proteome pulls out of prostate test
Tuesday, 15 July, 2008
Proteome Systems [ASX: PXL] has stopped development of a prostate cancer diagnostics test, after concluding that bringing the product to market would take too long.
Proteome had discovered cancerous prostate tissues demonstrate increased expression of Human Carcinoma Antigen [HCA], and developed an assay for detection of HCA in semen samples.
But the company concluded that developing the assay for commercialisation would take too long and consume too many resources.
A spokesperson for the company said Proteome was committed to projects with near-term revenue potential.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
